J 2013

microRNAs in nociceptive circuits as predictors of future clinical applications

KRESS, Michaela; Alexander HÜTTENHOFER; Marc LANDRY; Rohini KUNER; Alexandre FAVEREAUX et al.

Základní údaje

Originální název

microRNAs in nociceptive circuits as predictors of future clinical applications

Autoři

KRESS, Michaela; Alexander HÜTTENHOFER; Marc LANDRY; Rohini KUNER; Alexandre FAVEREAUX; David GREENBERG; Josef BEDNAŘÍK; Paul HEPPENSTALL; Florian KRONENBERG; Marzia MALCANGIO; Heike RITTNER; Nurcan ÜÇEYLER; Zlatko TRAJANOSKI; Peter MOURITZEN; Frank BIRKLEIN; Claudia SOMMER a Hermona SOREQ

Vydání

Frontiers in Molecular Neuroscience, Lausanne, Frontiers Research Foundation, 2013, 1662-5099

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/13:00071637

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Antagomir; Biomarker; Chronic pain; miRNA expression patterns; miRNA polymorphisms; miRNA-based analgesic; miRNA-based diagnostics; Polymorphism

Příznaky

Recenzováno
Změněno: 29. 4. 2014 15:04, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain, and non-coding RNAs - and microRNAs (miRNAs) in particular - regulate both immune and neuronal processes. Specifically, miRNAs control macromolecular complexes in neurons, glia and immune cells and regulate signals used for neuro-immune communication in the pain pathway. Therefore, miRNAs may be hypothesized as critically important master switches modulating chronic pain. In particular, understanding the concerted function of miRNA in the regulation of nociception and endogenous analgesia and defining the importance of miRNAs in the circuitries and cognitive, emotional and behavioral components involved in pain is expected to shed new light on the enigmatic pathophysiology of neuropathic pain, migraine and complex regional pain syndrome. Specific miRNAs may evolve as new druggable molecular targets for pain prevention and relief. Furthermore, predisposing miRNA expression patterns and inter-individual variations and polymorphisms in miRNAs and/or their binding sites may serve as biomarkers for pain and help to predict individual risks for certain types of pain and responsiveness to analgesic drugs. miRNA-based diagnostics are expected to develop into hands-on tools that allow better patient stratification, improved mechanism-based treatment, and targeted prevention strategies for high risk individuals.